Clinical proton MR spectroscopy in central nervous system disorders

Radiology

Volumn 270, Issue 3, 2014, Pages 658-679

  Öz, Gülin ^a   Alger, Jeffry R ^a   Barker, Peter B ^a   Bartha, Robert ^a   Bizzi, Alberto ^a   Boesch, Chris ^a   Bolan, Patrick J ^a   Brindle, Kevin M ^a   Cudalbu, Cristina ^a   Dinçer, Alp ^a   Dydak, Ulrike ^a   Emir, Uzay E ^a   Frahm, Jens ^a   Gilberto González, Ramón ^a   Gruber, Stephan ^a   Gruetter, Rolf ^a   Gupta, Rakesh K ^a   Heerschap, Arend ^a   Henning, Anke ^a   Hetherington, Hoby P ^a   Howe, Franklyn A ^a   Hüppi, Petra S ^a   Hurd, Ralph E ^a   Kantarci, Kejal ^a   Klomp, Dennis W J ^a   Kreis, Roland ^a   Kruiskamp, Marijn J ^a   Leach, Martin O ^a   Lin, Alexander P ^a   Luijten, Peter R ^a   Marjańska, Małgorzata ^a   Maudsley, Andrew A ^a   Meyerhoff, Dieter J ^a   Mountford, Carolyn E ^a   Nelson, Sarah J ^a   Pamir, Necmettin ^a   Pan, Jullie W ^a   Peet, Andrew C ^a   Poptani, Harish ^a,a   Posse, Stefan ^a   Pouwels, Petra J W ^a   Ratai, Eva Maria ^a   Ross, Brian D ^a   Scheenen, Tom W J ^a   Schuster, Christian ^a   Smith, Ian C P ^a   Soher, Brian J ^a   Tkáč, Ivan ^a   Vigneron, Daniel B ^a   Kauppinen, Risto A ^a   more..

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTROCYTOMA; CELL DENSITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CONTRAST ENHANCEMENT; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; EPILEPSY; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMAGE ANALYSIS; IMAGE PROCESSING; METABOLIC DISORDER; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SIGNAL NOISE RATIO; TRAUMATIC BRAIN INJURY;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84895440282     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13130531     Document Type: Review

References (177)

1. Bottomley PA. Selective volume method for performing localized NMR spectroscopy. U.S. patent 4,480,228. 1984.
2. Ordidge RJ, Bendall MR, Gordon RE, Connelly A. Volume selection for in vivo biological spectroscopy. In: Govil G, Khetrapal CL, Saran A, eds. Magnetic resonance in biology and medicine. New Delhi, India: McGraw Hill, 1985; 387-397.
3. Frahm J, Merboldt KD, Hanicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson 1987;72(3):502-508.
4. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn Reson Med 1989;9(1):126-131.
5. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14(1):154-159.
6. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172(2):541-548.
7. Bottomley PA. The trouble with spectroscopy papers. Radiology 1991;181(2):344-350.
8. Lin AP, Tran TT, Ross BD. Impact of evidence-based medicine on magnetic resonance spectroscopy. NMR Biomed 2006;19(4):476-483.
9. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11(2):88-94.
10. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13(3):129-153.
11. De Graaf RA. In vivo NMR spectroscopy: principles and techniques. 2nd ed. Hoboken, NJ: Wiley, 2007.
12. Gupta RK. Magnetic resonance spectroscopy in intracranial infection. In: Gillard JH, Waldman AD, Barker PB, eds. Clinical MR neuroimaging. 2nd ed. London, England: Cambridge University Press, 2010; 426-454.
13. 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49(2):223-232.
14. Oz G, Tkac I, Charnas LR, et al. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology 2005;64(3):434-441.
15. 1H-MRS. J Comput Assist Tomogr 2005;29(1):136-139.
16. Fein G, Meyerhoff DJ. Ethanol in human brain by magnetic resonance spectroscopy: correlation with blood and breath levels, relaxation, and magnetization transfer. Alcohol Clin Exp Res 2000;24(8):1227-1235.
17. 1H NMR spectra with increased magnetic field strength. J Magn Reson 1998;135(1):260-264.
18. Otazo R, Mueller B, Ugurbil K, Wald L, Posse S. Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging. Magn Reson Med 2006;56(6): 1200-1210.
19. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989;11(1):47-63.
20. Mlynarik V, Gruber S, Moser E. Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR Biomed 2001;14(5):325-331.
21. 1H-magnetic resonance spectroscopy of human brain: influence of composition and parameterization of the basis set in linear combination model-fitting. Magn Reson Med 2002;48(3):440-453.
22. Mekle R, Mlynarik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61(6):1279-1285.
23. 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009;62(4):868-879.
24. 1H NMR spectroscopy of the human brain at 9.4 T: initial results. J Magn Reson 2010;206(1):74-80.
25. 1H NMR spectroscopy in different regions of human brain in vivo at 7 T: T2 relaxation times and concentrations of cerebral metabolites. NMR Biomed 2012;25(2):332-339.
26. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992;59(1):55-61.
27. Tallan HH. Studies on the distribution of Nacetyl- L-aspartic acid in brain. J Biol Chem 1957;224(1):41-45.
28. Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2(3):131-134.
29. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4(2):47-52.
30. Rigotti DJ, Inglese M, Gonen O. Wholebrain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007;28(10):1843-1849.
31. 1H MRS studies in vivo. Neuroreport 1996;7(8):1397-1400.
32. Pouwels PJ, Kruse B, Korenke GC, Mao X, Hanefeld FA, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 1998;29(5):254-264.
33. 1H MR spectroscopy metabolite measurements. Radiology 2008;248(1):210-220.
34. Licata SC, Renshaw PF. Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction. Ann N Y Acad Sci 2010;1187:148-171.
35. Richards TL. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR Am J Roentgenol 1991;157(5):1073-1078.
36. Wardlaw JM, Marshall I, Wild J, Dennis MS, Cannon J, Lewis SC. Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnor malities in the infarct, blood flow, and clinical outcome. Stroke 1998;29(8):1618-1624.
37. Groenendaal F, Veenhoven RH, van der Grond J, Jansen GH, Witkamp TD, de Vries LS. Cerebral lactate and N-acetylaspartate/choline ratios in asphyxiated fullterm neonates demonstrated in vivo using proton magnetic resonance spectroscopy. Pediatr Res 1994;35(2):148-151.
38. Lange T, Dydak U, Roberts TP, Rowley HA, Bjeljac M, Boesiger P. Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 2006;27(4):895-901.
39. Gill SS, Thomas DG, Van Bruggen N, et al. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J Comput Assist Tomogr 1990;14(4):497-504.
40. 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn Reson Med 1992;24(1):123-136.
41. 1H NMR spectroscopy for three types of human brain and nervous system tumours. NMR Biomed 1995;8(6):253-264.
42. Hourani R, Brant LJ, Rizk T, Weingart JD, Barker PB, Horska A. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? AJNR Am J Neuroradiol 2008;29(2):366-372.
43. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24(10):1989-1998.
44. Garcia-Gomez JM, Luts J, Julia-Sape M, et al. Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. MAGMA 2009;22(1):5-18.
45. 1H MRS: a multi-centre study. Eur J Cancer 2013;49(3):658-667.
46. Tate AR, Underwood J, Acosta DM, et al. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006;19(4):411-434.
47. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDHmutated patients with gliomas. Nat Med 2012;18(4):624-629.
48. 1H MRS for typing and grading of brain tumours. NMR Biomed 2012;25(4):661-673.
49. 1H MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed 2007;20(8):763-770.
50. Crawford FW, Khayal IS, McGue C, et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 2009;91(3):337-351.
51. 1H-MRS be of clinical value? Br J Radiol 2003;76(907):459-463.
52. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16(8):1593-1603.
53. Kovanlikaya A, Panigrahy A, Krieger MD, et al. Untreated pediatric primitive neuroectodermal tumor in vivo: quantitation of taurine with MR spectroscopy. Radiology 2005;236(3):1020-1025.
54. 1H MRS at 1.5 Tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR. NMR Biomed 2010;23(1):80-87.
55. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas. J Neurosurg 2007;106(4):660-666.
56. Chang SM, Nelson S, Vandenberg S, et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 2009;92(3): 401-415.
57. Chawla S, Zhang Y, Wang S, et al. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr 2010;34(6):836-841.
58. 1H MRSI of the peripheral edematous region of human brain tumors in the differentiation between glioblastoma, metastasis, and meningioma. J Magn Reson Imaging 2012;36(5):1072-1082.
59. Al-Okaili RN, Krejza J, Woo JH, et al. Intraaxial brain masses: MR imaging-based diagnostic strategy-initial experience. Radiology 2007;243(2):539-550.
60. 1H-MR spectroscopy in the human spinal cord. AJNR Am J Neuroradiol 2013;34(9):1682-1689.
61. Steffen-Smith EA, Shih JH, Hipp SJ, Bent R, Warren KE. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neurooncol 2011;105(2):365-373.
62. Bluml S, Panigrahy A, Laskov M, et al. Elevated citrate in pediatric astrocytomas with malignant progression. Neurooncol 2011;13(10):1107-1117.
63. Wilson M, Cummins CL, Macpherson L, et al. Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours. Eur J Cancer 2013;49(2):457-464.
64. Einstein DB, Wessels B, Bangert B, et al. Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;84(3):668-674.
65. 1H-MRSI metabolites in gliomas. Neuroimage 2004;23(2):454-461.
66. Kallenberg K, Bock HC, Helms G, et al. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009;253(3):805-812.
67. 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. Magn Reson Med 2008;59(1):1-6.
68. Pamir MN, Ozduman K, Dincer A, Yildiz E, Peker S, Ozek MM. First intraoperative, shared-resource, ultrahigh-field 3-Tesla magnetic resonance imaging system and its application in low-grade glioma resection. J Neurosurg 2010;112(1):57-69.
69. Fink JR, Carr RB, Matsusue E, et al. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for dis tinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012;35(1):56-63.
70. Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90(4): 781-786.
71. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52(4):297-306.
72. 18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci 2010;17(1):50-53.
73. 1Hspectroscopy in developing human brain. Pediatr Res 1991;30(6):574-578.
74. van der Knaap MS, van der Grond J, van Rijen PC, Faber JA, Valk J, Willemse K. Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain. Radiology 1990;176(2):509-515.
75. Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases. Brain Dev 1991;13(6):410-416.
76. Lodygensky GA, Menache CC, Huppi PS. Magnetic resonance imaging's role in the care of the infant at risk for brain injury. In: Perlman JM, ed. Neurology: neonatology questions and controversies. 2nd ed. Amsterdam, the Netherlands: Elsevier, 2013.
77. Hanrahan JD, Cox IJ, Edwards AD, et al. Persistent increases in cerebral lactate concentration after birth asphyxia. Pediatr Res 1998;44(3):304-311.
78. Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009;361(14):1349-1358.
79. van der Knaap MS, Pouwels PJ. Magnetic resonance spectroscopy: basic principles and application in white matter disorders. In: van der Knaap MS, Valk J, eds. Magnetic resonance of myelination and myelin disorders. 3rd ed. Berlin, Germany: Springer, 2005; 859-880.
80. Frahm J, Hanefeld F. Localized proton magnetic resonance spectroscopy of brain disorders in childhood. In: Bachelard HS, ed. Magnetic resonance spectroscopy and imaging in neurochemistry. New York, NY: Plenum, 1997; 329-402.
81. 1H NMR spectroscopy in inborn errors of metabolism: body fluid NMR spectroscopy and in vivo MR spectroscopy. 2nd ed. Heilbronn, Germany: SPS Verlagsgesellschaft, 2007.
82. Heindel W, Kugel H, Roth B. Noninvasive detection of increased glycine content by proton MR spectroscopy in the brains of two infants with nonketotic hyperglycinemia. AJNR Am J Neuroradiol 1993; 14(3):629-635.
83. 1H magnetic resonance spectroscopy. Ann Neurol 1991;29(2):218-221.
84. Wilichowski E, Pouwels PJ, Frahm J, Hanefeld F. Quantitative proton magnetic resonance spectroscopy of cerebral metabolic disturbances in patients with MELAS. Neuropediatrics 1999;30(5):256-263.
85. Bruhn H, Kruse B, Korenke GC, et al. Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders. J Comput Assist Tomogr 1992;16(3):335-344.
86. Zand DJ, Simon EM, Pulitzer SB, et al. In vivo pyruvate detected by MR spectroscopy in neonatal pyruvate dehydrogenase deficiency. AJNR Am J Neuroradiol 2003;24(7):1471-1474.
87. Ghezzi D, Goffrini P, Uziel G, et al. SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet 2009;41(6):654-656.
88. Ohlenbusch A, Edvardson S, Skorpen J, et al. Leukoencephalopathy with accumulated succinate is indicative of SDHAF1 related complex II deficiency. Orphanet J Rare Dis 2012;7(1):69.
89. Manley BJ, Sokol J, Cheong JL. Intracerebral blood and MRS in neonatal nonketotic hyperglycinemia. Pediatr Neurol 2010;42(3):219-222.
90. 1H NMR spectroscopy in Canavan's disease: a report of two cases. Magn Reson Med 1991;19(2):439-445.
91. Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S, Salomons GS. Creatine deficiency syndromes. GeneReviews 2009. http://www.ncbi.nlm.nih.gov/books/ NBK3794/. Updated August 18, 2011. Accessed April 27, 2012.
92. Stockler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 1996;348(9030):789-790.
93. Ndika JD, Johnston K, Barkovich JA, et al. Developmental progress and creatine restoration upon long-term creatine supplementation of a patient with arginine:glycine amidinotransferase deficiency. Mol Genet Metab 2012;106(1):48-54.
94. van de Kamp JM, Pouwels PJ, Aarsen FK, et al. Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. J Inherit Metab Dis 2012; 35(1):141-149.
95. Bizzi A, Bugiani M, Salomons GS, et al. X-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8. Ann Neurol 2002;52(2):227-231.
96. Wiame E, Tyteca D, Pierrot N, et al. Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem J 2010;425(1):127-136.
97. Martin E, Capone A, Schneider J, Hennig J, Thiel T. Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? Ann Neurol 2001;49(4):518-521.
98. Pouwels PJ, Brockmann K, Kruse B, et al. Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatr Res 1999;46(4):474-485.
99. Davison JE, Hendriksz CJ, Sun Y, Davies NP, Gissen P, Peet AC. Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter syndrome). J Inherit Metab Dis 2010;33(Suppl 3):395-399.
100. Davison JE, Davies NP, Wilson M, et al. MR spectroscopy-based brain metabolite profiling in propionic acidaemia: metabolic changes in the basal ganglia during acute decompensation and effect of liver transplantation. Orphanet J Rare Dis 2011;6:19.
101. Langlois JA, Rutland-Brown W, Thomas KE. The incidence of traumatic brain injury among children in the United States: differences by race. J Head Trauma Rehabil 2005;20(3):229-238.
102. Aaen GS, Holshouser BA, Sheridan C, et al. Magnetic resonance spectroscopy predicts outcomes for children with nonaccidental trauma. Pediatrics 2010;125(2):295-303.
103. 1H- magnetic resonance spectroscopy. J Clin Invest 1996;97(5):1142-1154.
104. Bizzi A, Castelli G, Bugiani M, et al. Classification of childhood white matter disorders using proton MR spectroscopic imaging. AJNR Am J Neuroradiol 2008;29(7): 1270-1275.
105. van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology 2006;241(2):510-517.
106. Cartier N, Aubourg P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr Opin Mol Ther 2008;10(5):471-478.
107. Eichler FS, Barker PB, Cox C, et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 2002;58(6):901-907.
108. Wilken B, Dechent P, Brockmann K, et al. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatrics 2003;34(5):237-246.
109. Kruse B, Hanefeld F, Christen HJ, et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 1993;241(2):68-74.
110. Eichler F, Grodd W, Grant E, et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol 2009;30(10):1893-1897.
111. i Dali C, Hanson LG, Barton NW, Fogh J, Nair N, Lund AM. Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology 2010; 75(21):1896-1903.
112. Ding XQ, Bley A, Kohlschutter A, Fiehler J, Lanfermann H. Long-term neuroimaging follow-up on an asymptomatic juvenile metachromatic leukodystrophy patient after hematopoietic stem cell transplantation: evidence of myelin recovery and ongoing brain maturation. Am J Med Genet A 2012;158A(1):257-260.
113. Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009;19(1):45-58.
114. Davie CA, Hawkins CP, Barker GJ, et al. Detection of myelin breakdown products by proton magnetic resonance spectroscopy. Lancet 1993;341(8845):630- 631.
115. Hannoun S, Bagory M, Durand-Dubief F, et al. Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis. PLoS ONE 2012;7(3): e32525.
116. Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 2005;53(2):256-266.
117. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58(1): 65-70.
118. Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 2002;249(10):1382-1390.
119. De Stefano N, Filippi M, Miller D, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69(20):1942- 1952.
120. de Graaf WL, Kilsdonk ID, Lopez-Soriano A, et al. Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. Eur Radiol 2013;23(2):528-540.
121. Bizzi A, Uluǧ AM, Crawford TO, et al. Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 2001;22(6):1125-1130.
122. Chang KH, Song IC, Kim SH, et al. In vivo single-voxel proton MR spectroscopy in intracranial cystic masses. AJNR Am J Neuroradiol 1998;19(3):401-405.
123. Agarwal M, Chawla S, Husain N, Jaggi RS, Husain M, Gupta RK. Higher succinate than acetate levels differentiate cerebral degenerating cysticerci from anaerobic abscesses on in-vivo proton MR spectroscopy. Neuroradiology 2004;46(3):211-215.
124. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010;75(19):1702-1710.
125. 1H MRS study. Neurology 2000;55(2): 210-217.
126. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000;355(9216):1696-1697.
127. Oz G, Hutter D, Tkac I, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord 2010;25(9):1253-1261.
128. Unschuld PG, Edden RA, Carass A, et al. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord 2012;27(7):895-902.
129. 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007;28(9):1330-1339.
130. Griffith HR, Stewart CC, den Hollander JA. Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. Int Rev Neurobiol 2009;84:105-131.
131. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2011; 32(5):802-810.
132. Oz G, Iltis I, Hutter D, Thomas W, Bushara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 2011;10(2):208-217.
133. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993;187(2):433-437.
134. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998;8(4):809-822.
135. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66(5):718-722.
136. Kantarci K, Boeve BF, Wszolek ZK, et al. MRS in presymptomatic MAPT mutation carriers: a potential biomarker for taumediated pathology. Neurology 2010;75(9): 771-778.
137. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160(11):2003-2011.
138. 1H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog Neuropsycho pharmacol Biol Psychiatry 2008;32(3): 786-793.
139. Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(1): 104-110.
140. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342(5):314-319.
141. Del Felice A, Beghi E, Boero G, et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia 2010;51(1):37-42.
142. Wiebe S, Jette N. Epilepsy surgery utilization: who, when, where, and why? Curr Opin Neurol 2012;25(2):187-193.
143. Englot DJ, Wang DD, Rolston JD, Shih TT, Chang EF. Rates and predictors of longterm seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis. J Neurosurg 2012;116(5): 1042-1048.
144. Siesjo BK. Brain energy metabolism. London, England: Wiley, 1978.
145. Pan JW, Williamson A, Cavus I, et al. Neurometabolism in human epilepsy. Epilepsia 2008;49(Suppl 3):31-41.
146. 1H MR spectroscopic images for presurgical evaluation. Radiology 2001;218(1): 144-151.
147. Connelly A, Jackson GD, Duncan JS, King MD, Gadian DG. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 1994;44(8):1411-1417.
148. Simister RJ, McLean MA, Barker GJ, Duncan JS. Proton MR spectroscopy of metabolite concentrations in temporal lobe epilepsy and effect of temporal lobe resection. Epilepsy Res 2009;83(2-3):168-176.
149. Maudsley AA, Domenig C, Ramsay RE, Bowen BC. Application of volumetric MR spectroscopic imaging for localization of neocortical epilepsy. Epilepsy Res 2010;88(2-3):127-138.
150. Pan JW, Duckrow RB, Spencer DD, Avdievich NI, Hetherington HP. Selective homonuclear polarization transfer for spectroscopic imaging of GABA at 7T. Magn Reson Med 2013;69(2):310-316.
151. 1H magnetic resonance spectroscopy in preoperative evaluation for epilepsy surgery: a meta-analysis. Epilepsy Res 2006;71(2-3): 149-158.
152. Fountas KN, Tsougos I, Gotsis ED, Giannakodimos S, Smith JR, Kapsalaki EZ. Temporal pole proton preoperative magnetic resonance spectroscopy in patients undergoing surgery for mesial temporal sclerosis. Neurosurg Focus 2012;32(3):E3.
153. Pan JW, Avdievich N, Hetherington HP. J-refocused coherence transfer spectroscopic imaging at 7 T in human brain. Magn Reson Med 2010;64(5):1237- 1246.
154. Cross JH, Connelly A, Jackson GD, Johnson CL, Neville BG, Gadian DG. Proton magnetic resonance spectroscopy in children with temporal lobe epilepsy. Ann Neurol 1996;39(1):107-113.
155. Gonzalez RG. Clinical MRI of acute ischemic stroke. J Magn Reson Imaging 2012; 36(2):259-271.
156. van der Toorn A, Verheul HB, Berkelbach van der Sprenkel JW, Tulleken CA, Nicolay K. Changes in metabolites and tissue water status after focal ischemia in cat brain assessed with localized proton MR spectroscopy. Magn Reson Med 1994;32(6):685-691.
157. Sager TN, Laursen H, Hansen AJ. Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat. J Cereb Blood Flow Metab 1995;15(4):639-646.
158. Saunders DE. MR spectroscopy in stroke. Br Med Bull 2000;56(2):334-345.
159. 1H MR spectroscopy and diffusionweighted MRI improves the prediction of stroke outcome. Neurology 2000;55(4): 498-505.
160. Petroff OA, Graham GD, Blamire AM, et al. Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology 1992;42(7):1349-1354.
161. Klijn CJ, Kappelle LJ, van der Grond J, Algra A, Tulleken CA, van Gijn J. Magnetic resonance techniques for the identification of patients with symptomatic carotid artery occlusion at high risk of cerebral ischemic events. Stroke 2000;31(12):3001-3007.
162. Emir UE, Tuite PJ, Oz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 Tesla proton MRS. PLoS ONE 2012;7(1):e30918.
163. 1H-MRSI of the human brain at 7T with slice-selective adiabatic refocusing pulses. MAGMA 2008;21(1-2):95-101.
164. 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004; 17(6):361-381.
165. Soher BJ, Semanchuk P, Todd D, Steinberg J, Young K. Vespa: integrated applications for RF pulse design, spectral simulation and MRS data analysis [abstr]. In: Proceedings of the Nineteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2011; 1410.
166. 1H spectra with LCModel. NMR Biomed 2001;14(4):260-264.
167. Scheidegger O, Wingeier K, Stefan D, et al. Optimized quantitative magnetic resonance spectroscopy for clinical routine. Magn Reson Med 2013;70(1):25-32.
168. 1H spectroscopic imaging with automated quantification. Magn Reson Med 2008;60(3):542-547.
169. Schirmer T, Auer DP. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain. NMR Biomed 2000;13(1):28-36.
170. 1H-MR spectroscopy of hippocampal structures in healthy adults at 1.5 Tesla: how reproducible are the results? NMR Biomed 2005;18(3):195-201.
171. Li BS, Babb JS, Soher BJ, Maudsley AA, Gonen O. Reproducibility of 3D proton spectroscopy in the human brain. Magn Reson Med 2002;47(3):439-446.
172. 1H MRSI of the human brain at 3T with adiabatic slice-selective refocusing pulses: reproducibility and variance in a dual center setting. J Magn Reson Imaging 2010;31(1):61-70.
173. Gasparovic C, Bedrick EJ, Mayer AR, et al. Test-retest reliability and reproducibility of short-echo-time spectroscopic imaging of human brain at 3T. Magn Reson Med 2011;66(2):324-332.
174. Terpstra M, Emir UE, Eberly LE, Oz G. Test-retest repeatability of human neurochemical profiles measured at 3 versus 7 T [abstr]. In: Proceedings of the Twentieth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2012; 1739.
175. Oz G, Tkač I. Short-echo, single-shot, fullintensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem. Magn Reson Med 2011;65(4):901-910.
176. Smith IC, Somorjai RL. Deriving biomedical diagnostics from NMR spectroscopic data. Biophys Rev 2011;3(1):47-52.
177. Somorjai RL. Creating robust, reliable, clinically relevant classifiers from spectroscopic data. Biophys Rev 2009;1(4):201-211.